PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO JC56
APR 22 2005
PATENT & TRADEMARK OFFICE

DOCKET NO. B0192.70051US00

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: 10/500,832	DOCKET NO.: B0192.70051US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	INT'L. FILING DATE: 01/07/03	CONFIRMATION NO.: 8927
	APPLICANT: Frank Karlsen	
Sheet 1 of 2	GROUP ART UNIT: ~~1645~~ 1637	EXAMINER: ~~Not yet assigned~~ B. bic

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Document Number	U.S. Patent Document Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
	A1	5,639,871	A	Bauer, Heidi M., et al.	06/17/1997

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document Office/ Country	Number	Kind Code	Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
	B1	EP	0 662 518	A2	AMOCO Corp.	07-12-1995	
	B2	EP	0 373 352	A2	Behringwerke Aktiengesellschaft	06-20-1990	N
	B3	WO	03/057927	A2	Norchip AS	07-17-2003	
	B4	WO	03/057914	A2	Norchip AS	07-17-2003	
	B5	WO	01/73135	A2	Biosearch International Pty. Ltd	11-04-2001	
	B6	WO	99/29890	A2	Digene Corporation	06-17-1999	
	B7	WO	94/26934	A2	Baxter Diagnostics, Inc.	11-24-1994	
	B8	WO	90/02821	A1	Cetus Corp.	03-22-1990	
	B9	WO	02/08460	A2	Norchip AS	01-31-2002	
	B10	WO	00/00638	A2	Deursen Petrus Bernardus Hugo	01-06-2000	
	B11	WO	91/08312	A2	Gene-Trak Systems	06-13-1991	
	B12	EP	0 402 132	A2	Takara Shuzo Co., Ltd.	12-12-1990	
	B13	EP	0 243 221	A1	Institut Pasteur	10-28-1987	
	B14	EP	0 774 518	A2	Gen Probe Inc.	05-21-1997	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	C1	SMITS, H.L., et al. "Application of the NASBA nucleic acid amplification method for the detection of human papillomavirus type 16 E6-E7 transcripts," Journal of Virological Methods, Amsterdam, NL, Vol. 54, No. 1, 1995, pgs. 75-81		
	C2	CORNELISSEN, M.T. E. et al., "Uniformity of the splicing pattern of the E6/E7 transcripts in human papillomavirus type 16-transformed human fibroblasts, human cervical premalignant lesions and carcinomas," Journal of General Virology, Society for General Microbiology, Reading, GB, Vol. 71, No. Part 5, (May 1, 1990), pgs. 1243-1246		

OIPE JC56 APR 22 2005 PATENT & TRADEMARK OFFICE

FORM PTO-1449/A and B (Modified)	APPLICATION NO.: 10/500,832	DOCKET NO.: B0192.70051US00
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	INT'L. FILING DATE: 01/07/03	CONFIRMATION NO.: 8927
	APPLICANT: Frank Karlsen	
	GROUP ART UNIT: ~~1645~~ B37	EXAMINER: ~~Not yet assigned~~ B.G.C
Sheet 2 of 2		

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)	
	C3	MCNICOL, Patricia et al., "Expression of human papillomavirus type 16 E6-E7 open reading frame varies quantitatively in biopsy tissue from different grades of cervical intraepithelial neoplasia,," Journal of Clinical Microbiology, Vol. 33, No. 5, 1995, pgs 1169-1173		
	C4	JEON, Saewha, et al., "Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: Implications for cervical carcinogenesis," Proceedings of the National Academy of Sciences of the U.S., Vol. 92, No. 5, 1995, pgs 1654-1658		
	C5	LEONE, et al., "Molecular beacon probes combined with amplification by NASBA enable homogeneous, real-time detection of RNA," Nucleic Acids Research, 1998, Vol. 26, No. 9, pgs. 2150-2155		
	C6	WALBOOMERS, Jan M.M., et al., "Human papillomavirus is a necessary cause of invasive cervical cancer worldwide," Journal of Pathology, J. Pathol. 189: pgs. 12-19 (1999)		
	C7	BOSCH, F. Xavier, et al., "Prevalence of Human papillomavirus in cervical cancer: a worldwide perspective," Journal of the National Cancer Institute, Vol. 87, No. 11, June 7, 1995, pgs. 796-802		
	C8	KATO, Satoshi, et al., "Detection of human papillomaviruses in cervical neoplasias using multiple sets of generic polymerase chain reaction primers," Gynecologic Oncology, Vol. 81, No. 1, (April, 2001) pgs. 47-52		
	C9	IWASAWA, Akihiko, et al., "Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction," American Cancer Society, Vol. 77, No. 11, (6/1/96), pgs. 2275-2279		
	C10	DOEBERITZ, M., "New molecular tools for efficient screening of cervical cancer," Vol. 17, 2001, pgs. 123-128		
	C11	LANHAM, S., et al., "HPV detection and measurement of HPV-16, telomerase, and survivin transcripts in colposcopy clinic patients," J. Clin. Pathol., Vol. 54, 2001, pgs. 304-308		
	C12	COUTLEE, F., et al., "Detection of transcripts of human papillomaviruses 16 and 18 in Cancer-derived cell lines and cervical biopsies by enzyme immunoassay for DNA-RNA hybrids following solution hybridization," J. Clin. Micro, Vol. 29, 1991, pgs. 968-974		
	C13	DATABASE, "HPV sequence Database, 'Online! 'Los Alamos National Laboratory; 09-1997, Los Alamos National Laboratory; "Human papilloma viruses 1997 compendium," pgs. E6-10 – E6-24		
	C14	WU SHUENN-Jue L., et al. "Detection of dengue viral RNA using a nucleic acid sequence-based amplification assay," Journal of Clinical Microbiology, Vol. 39, No. 8, August 2001		

EXAMINER	DATE CONSIDERED
	1/11/07

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __ , filed __ , and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office has waived the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications.]